The epidermal growth factor receptor: from development to tumorigenesis

被引:276
作者
Sibilia, Maria [1 ]
Kroismayr, Renate [1 ]
Lichtenberger, Beate M. [1 ]
Natarajan, Anuradha [1 ]
Hecking, Manfred [1 ]
Holcmann, Martin [1 ]
机构
[1] Med Univ Vienna, Inst Canc Res, Dept Med 1, A-1090 Vienna, Austria
基金
奥地利科学基金会;
关键词
epidermal growth factor receptor (EGFR); knock-out; transgenic; mouse development; lung; liver; skin; bone; placenta; heart; human cancer;
D O I
10.1111/j.1432-0436.2007.00238.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The epidermal growth factor receptor (EGFR) is activated by many ligands and belongs to a family of tyrosine kinase receptors, including ErbB2, ErbB3, and ErbB4. These receptors are de-regulated in many human tumors, and EGFR amplification, overexpression, and mutations are detected at a high frequency in carcinomas and glioblastomas, which are tumors of epithelial and glial origin, respectively. From the analysis of EGFR-deficient mice, it seems that the cell types mostly affected by the absence of EGFR are epithelial and glial cells, the same cell types where the EGFR is found to be overexpressed in human tumors. Therefore, it is important to define molecularly the function of EGFR signaling in the development of these cell types, because this knowledge will be of fundamental importance to understand how aberrant EGFR signaling can lead to tumor formation and progression. A molecular understanding of the pathways that control the development of a given tissue or cell type will also provide the basis for developing better combination therapies targeting different key components of the EGFR signaling network in the respective cancerous cells. Here, we will review the current knowledge, mostly derived from the analysis of genetically modified mice and cells, about the function of the EGFR in specific organs and tissues and in sites where the EGFR is found to be overexpressed in human tumors.
引用
收藏
页码:770 / 787
页数:18
相关论文
共 131 条
[11]   The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted [J].
Brown, K ;
Strathdee, D ;
Bryson, S ;
Lambie, W ;
Balmain, A .
CURRENT BIOLOGY, 1998, 8 (09) :516-524
[12]  
Casanova ML, 2002, CANCER RES, V62, P3402
[13]   Expression of epidermal growth factor in transgenic mice causes growth retardation [J].
Chan, SY ;
Wong, RWC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (49) :38693-38698
[14]   Down-regulation of osteoblastic cell differentiation by epidermal growth factor receptor [J].
Chien, HH ;
Lin, WL ;
Cho, MI .
CALCIFIED TISSUE INTERNATIONAL, 2000, 67 (02) :141-150
[15]   Malignant melanoma: genetics and therapeutics in the genomic era [J].
Chin, Lynda ;
Garraway, Levi A. ;
Fisher, David E. .
GENES & DEVELOPMENT, 2006, 20 (16) :2149-2182
[16]   The central role of osteoblasts in the metastasis of prostate cancer [J].
Choueiri, Michel B. ;
Tu, Shi-Ming ;
Yu-Lee, Li-Yuan ;
Lin, Sue-Hwa .
CANCER AND METASTASIS REVIEWS, 2006, 25 (04) :601-609
[17]   Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype [J].
Cook, PW ;
Piepkorn, M ;
Clegg, CH ;
Plowman, GD ;
DeMay, JM ;
Brown, JR ;
Pittelkow, MR .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (09) :2286-2294
[18]   Essential role of RSK2 in c-Fos-dependent osteosarcoma development [J].
David, JP ;
Mehic, D ;
Bakiri, L ;
Schilling, AF ;
Mandic, V ;
Priemel, M ;
Idarraga, MH ;
Reschke, MO ;
Hoffmann, O ;
Amling, M ;
Wagner, EF .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (03) :664-672
[19]   Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene [J].
De Cesare, D ;
Jacquot, S ;
Hanauer, A ;
Sassone-Corsi, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (21) :12202-12207
[20]   Epidermal growth factor receptor expression in. neurofibromatosis type 1-related tumors and NF1 animal models [J].
DeClue, JE ;
Heffelfinger, S ;
Benvenuto, G ;
Ling, B ;
Li, SW ;
Rui, W ;
Vass, WC ;
Viskochil, D ;
Ratner, N .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (09) :1233-1241